The importance of early detection of chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 11, 2002, Pages 2-7

  Locatelli, Francesco ^a   Vecchio, Lucia Del ^a   Pozzoni, Pietro ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Cardiovascular disease; Chronic kidney disease; Referral; Renal replacement therapy

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; CALCIUM; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; KIDNEY RENIN; LOSARTAN; MELATONIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATE; RECOMBINANT ERYTHROPOIETIN; STEROID;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIALYSIS; DISEASE COURSE; DRUG EFFICACY; EARLY DIAGNOSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; METABOLIC DISORDER; MORBIDITY; MORTALITY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; SMOKING CESSATION;

EID: 0036408984     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_11.2     Document Type: Article

References (45)

1. Locatelli F, Valderrábano F, Hoenich N, Bommer J, Leunissen K, Cambi V. Progress in dialysis technology: membrane selection and patient outcome. Nephrol Dial Transplant 2000; 15: 1133-1139
2. US Renal Data System. USRDS 2000 Annual Data Report, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD: 2001
3. Locatelli F, Marcelli D, Conte F et al. For the Registro Lombardo Dialisi e Trapianto. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000; 15 [Suppl 5]: S69-S80
4. Lupi GP, Bisegna S, Marcelli D, Grassi C, Locatelli F. Epidemiology and follow-up of early chronic renal failure (CRF) in Lombardy population. Nephrol Dial Transplant 1997; 12: A105 [Abstract]
5. Jungers P, Chauveau P, Descamps-Latscha B et al. Age and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study. Nephrol Dial Transplant 1996; 11: 1542-1546
6. Jones C, McQuillan G, Kusek J et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32: 992-999
7. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [Suppl 3]: S112-S119
8. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192
9. Locatelli F, Marcelli D, Conte F et al. For the Registro Lombardo Dialisi e Trapianto. Patient selection affecting endstage renal disease outcome comparisons. Kidney Int 2000; 57 [Suppl 74]: S94-S99
10. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet 1991; 337: 1299-1304
11. Klahr S, Levey AS, Beck GJ et al. and the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood pressure control on the progression of renal disease. N Engl J Med 1994; 330: 877-884
12. Locatelli F, Del Vecchio L. How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol Dial Transplant 1999; 14: 1360-1364
13. Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure. Nephrol Dial Transplant 2000; 15: 1986-1992
14. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
15. Levin NW, Hulbert-Shearon TE, Strawderman RL. Which causes of death are related to hyperphosphataemia in hemodialysis (HD) patients? J Am Soc Nephrol 1998; 9: 217A
16. Amann K, Gross ML, London GM, Ritz E. Hyperphosphataemia-a silent killer of patients with renal failure? Nephrol Dial Transplant 1999; 14: 2085-2087
17. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762
18. Locatelli F, Del Vecchio L, D'Amico M, Andrulli S. Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13 [Suppl 18]: in press
19. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
20. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
21. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
22. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
23. Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000; 15: 650-658
24. Portales J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548
25. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256
26. Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int 1997; 51: 1669-1677
27. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 1994; 9: 1097-1102
28. Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000; 35: 687-694
29. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269
30. Samuelson O, Mulec H, Knight-Gibson C et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908-1915
31. Massy ZA, Khoa TN, Lacour B, Descamps-Latcha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999; 14: 2392-2397
32. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301
33. Noronha IL, Fujihara Ck, Zatz R. The inflammatory component in progressive renal disease-are interventions possible? Neprol Dial Transplant 2002; 17: 363-368
34. Cristol JP, Bosc JY, Badiou S et al. Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 1997; 12: 2312-2317
35. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-549
36. Islam KN, O'Bryne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000; 150: 217-224
37. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised place-controlled trial. Lancet 2000; 356: 1213-1218
38. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 1999; 55: 2477-2486
39. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoeitin administration. Am J Kidney Dis 2001; 37: 750-757
40. Jungers P, Zingraff J, Albouze G et al. Late referral to maintenance dialysis: detrimental consequences. Nephrol Dial Transplant 1993; 8: 1089-1093
41. Khan IH, Catto GR, Neil E, Macleod AM. Death during the first 90 days of dialysis: a case-control study. Am J Kidney Dis 1995; 25: 276-280
42. Roubicek C, Brunet P, Huiart L et al. Timing of nephrology referral: influence on mortality and morbidity. Am J Kidney Dis 2000; 36: 35-41
43. Jungers P, Massy ZA, Nguyen-Khoa T et al. Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant 2001; 16: 2357-2364
44. McLaughlin K, Manns B, Culleton B, Donaldson C, Taub K. An economic evaluation of early versus late referral of patients with progressive renal insufficiency. Am J Kidney Dis 2001; 38: 1122-1128
45. Jungers P. Late referral: loss of change for the patient, loss of money for societ. Nephrol Dial Transplant 2001; 17: 371-375